

Ref: FOI/GS/ID 4620

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

26 April 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Metastatic hepatocellular carcinoma patients.

You asked:

1 - In the past three months, how many metastatic hepatocellular carcinoma patients were treated with?

Sorafenib (Nexavar)

Other active systemic anti-cancer therapy

Other including palliative care

2 - In the past three months, how many metastatic renal cell carcinoma patients were treated with?

Sunitinib (Sutent)

Pazopanib (Votrient)

Everolimus (Afinitor)

Temsirolimus (Torisel)

Cabozantinib (Cometriq)

Nivolumab (Opdivo)

Axinitib (Inlyta)

Nivolumab + Ipilimumab (Opdivo + Yervoy)

Levatinib (Lenvima) + Everolimus (Afinitor)

Tivozanib (Fotivda)

Other active systemic anti-cancer therapy

Other including palliative care

3 - In the past 3 months, how many metastatic melanoma patients were treated with?

Pembrolizumab (Keytruda)

Nivolumab (Opdivo)

Ipilimumab (Yervoy)

Nivolumab + Ipilimumab (Opdivo + Yervoy)

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Dabrafenib (Tafinlar)

Vemurafenib (Zelboraf)

Vemurafenib + cobimetinib (Zelboraf _ Cotellic)
Other active systemic anti-cancer therapy
Other including palliative care

Trust response:

1 -

Sorafenib (Nexavar)	0
Other active systemic anti-cancer therapy	48
Other including palliative care	1

2 -

Sunitinib (Sutent)	5
Pazopanib (Votrient)	9
Everolimus (Afinitor)	0
Temsirolimus (Torisel)	0
Cabozantinib (Cometriq)	1
Nivolumab (Opdivo)	6
Axinitib (Inlyta)	5
Nivolumab + Ipilimumab (Opdivo + Yervoy)	0
Levatinib (Lenvima) + Everolimus (Afinitor)	0
Tivozanib (Fotivda)	0
Other active systemic anti-cancer therapy	2
Other including palliative care	10

3 -

Pembrolizumab (Keytruda)	17
Nivolumab (Opdivo)	2
Ipilimumab (Yervoy)	0
Nivolumab + Ipilimumab (Opdivo + Yervoy)	6
Dabrafenib + Trametinib (Tafinlar + Mekinist)	0
Dabrafenib (Tafinlar)	10
Vemurafenib (Zelboraf)	2
Vemurafenib + cobimetinib (Zelboraf _ Cotellic)	0
Other active systemic anti-cancer therapy	1
Other including palliative care	2